{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T13:45:36Z","timestamp":1782654336755,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00228-019-02729-7","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T15:06:40Z","timestamp":1565190400000},"page":"1565-1574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes"],"prefix":"10.1007","volume":"75","author":[{"given":"Anne","family":"Gardin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Shakeri-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Feller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Neelakantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Dumitras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"issue":"9","key":"2729_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrneurol.2013.148","volume":"9","author":"MW Koch","year":"2013","unstructured":"Koch MW, Cutter G, Stys PK, Yong VW, Metz LM (2013) Treatment trials in progressive MS--current challenges and future directions. Nat Rev Neurol 9(9):496\u2013503. \nhttps:\/\/doi.org\/10.1038\/nrneurol.2013.148","journal-title":"Nat Rev Neurol"},{"key":"2729_CR2","unstructured":"Atlas of MS 2013. http:\/\/www.msif.org\/wp-content\/uploads\/2014\/09\/Atlas-of-MS.pdf (accessed on 20 June, 2019)"},{"issue":"4","key":"2729_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.46.4.907","volume":"46","author":"F. D. Lublin","year":"1996","unstructured":"Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis. Results of an international survey 46 (4): 907\u2013911 DOI \nhttps:\/\/doi.org\/10.1212\/wnl.46.4.907","journal-title":"Neurology"},{"issue":"7","key":"2729_CR4","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"Antonio Scalfari","year":"2010","unstructured":"Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133 (Pt 7): 1914\u20131929 DOI \nhttps:\/\/doi.org\/10.1093\/brain\/awq118","journal-title":"Brain"},{"key":"2729_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.msard.2016.07.003","volume":"9","author":"G Giovannoni","year":"2016","unstructured":"Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T (2016) Brain health: time matters in multiple sclerosis. Mult Scler Relat Dis 9:S5\u2013S48. \nhttps:\/\/doi.org\/10.1016\/j.msard.2016.07.003","journal-title":"Mult Scler Relat Dis"},{"issue":"1","key":"2729_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","volume":"115","author":"V Brinkmann","year":"2007","unstructured":"Brinkmann V (2007) Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 115(1):84\u2013105. \nhttps:\/\/doi.org\/10.1016\/j.pharmthera.2007.04.006","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2729_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","volume":"167","author":"P Gergely","year":"2012","unstructured":"Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrom E (2012) The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol 167(5):1035\u20131047. \nhttps:\/\/doi.org\/10.1111\/j.1476-5381.2012.02061.x","journal-title":"Br J Pharmacol"},{"key":"2729_CR8","doi-asserted-by":"publisher","first-page":"135245851772135","DOI":"10.1177\/1352458517721355","volume":"24","author":"A Mannioui","year":"2017","unstructured":"Mannioui A, Vauzanges Q, Fini JB, Henriet E, Sekizar S, Azoyan L, Thomas JL, Pasquier DD, Giovannangeli C, Demeneix B, Lubetzki C, Zalc B (2017) The Xenopus tadpole: an in vivo model to screen drugs favoring remyelination. Mult Scler Houndmills, Basingstoke, England 24:1352458517721355. \nhttps:\/\/doi.org\/10.1177\/1352458517721355","journal-title":"Mult Scler Houndmills, Basingstoke, England"},{"issue":"6","key":"2729_CR9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1523\/jneurosci.4645-04.2005","volume":"25","author":"C Jaillard","year":"2005","unstructured":"Jaillard C, Harrison S, Stankoff B, Aigrot MS, Calver AR, Duddy G, Walsh FS, Pangalos MN, Arimura N, Kaibuchi K, Zalc B, Lubetzki C (2005) Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 25(6):1459\u20131469. \nhttps:\/\/doi.org\/10.1523\/jneurosci.4645-04.2005","journal-title":"J Neurosci"},{"issue":"10127","key":"2729_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallstr\u00f6m E, Dahlke F (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263\u20131273. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6","journal-title":"Lancet"},{"key":"2729_CR11","unstructured":"Prescribing information: Mayzent (siponimod). East Hanover, NJ: Novartis pharmaceuticals, 2019 (package insert)"},{"issue":"7","key":"2729_CR12","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1124\/dmd.117.079574","volume":"46","author":"U Glaenzel","year":"2018","unstructured":"Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, Gardin A (2018) Metabolism and disposition of Siponimod, a novel selective S1P1\/S1P5 agonist, in healthy volunteers and in vitro identification of human cytochrome P450 enzymes involved in its oxidative metabolism. Drug Metab Dispos 46(7):1001\u20131013. \nhttps:\/\/doi.org\/10.1124\/dmd.117.079574","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2729_CR13","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00228-017-2404-2","volume":"74","author":"Y Jin","year":"2018","unstructured":"Jin Y, Borell H, Gardin A, Ufer M, Huth F, Camenisch G (2018) In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. Eur J Clin Pharmacol 74(4):455\u2013464. \nhttps:\/\/doi.org\/10.1007\/s00228-017-2404-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2729_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40262-018-0700-3","volume":"58","author":"A Gardin","year":"2019","unstructured":"Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, Shakeri-Nejad K (2019) Effect of fluconazole Coadministration and CYP2C9 genetic polymorphism on Siponimod pharmacokinetics in healthy subjects. Clin Pharmacokinet 58(3):349\u2013361. \nhttps:\/\/doi.org\/10.1007\/s40262-018-0700-3","journal-title":"Clin Pharmacokinet"},{"key":"2729_CR15","unstructured":"Pharmacogene Variation Consortium (PharmVar). \nhttps:\/\/www.pharmvar.org\/gene\/CYP2C9\n\n. Accessed 1 April 2019"},{"issue":"1","key":"2729_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2133\/dmpk.DMPK-12-RV-085","volume":"28","author":"T Hirota","year":"2013","unstructured":"Hirota T, Eguchi S, Ieiri I (2013) Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinetics 28(1):28\u201337","journal-title":"Drug Metab Pharmacokinetics"},{"issue":"4","key":"2729_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/FPC.0b013e3283349e84","volume":"20","author":"D Van Booven","year":"2010","unstructured":"Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB (2010) Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 20(4):277\u2013281. \nhttps:\/\/doi.org\/10.1097\/FPC.0b013e3283349e84","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"2729_CR18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/cpt.1547","volume":"106","author":"Felix Huth","year":"2019","unstructured":"Huth F, Gardin A, Umehara KI, He H (2019) Prediction of the impact of CYP2C9 genotypes on the drug-drug interaction potential of Siponimod with PBPK modeling: a comprehensive approach for drug label recommendations. Clin Pharmacol Ther. \nhttps:\/\/doi.org\/10.1002\/cpt.1547","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"10","key":"2729_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1124\/dmd.104.000315","volume":"32","author":"N Isoherranen","year":"2004","unstructured":"Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32(10):1121\u20131131. \nhttps:\/\/doi.org\/10.1124\/dmd.104.000315","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"2729_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/00498254.2018.1425510","volume":"49","author":"K Krasulova","year":"2019","unstructured":"Krasulova K, Dvorak Z, Anzenbacher P (2019) In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A. Xenobiotica 49(1):36\u201342. \nhttps:\/\/doi.org\/10.1080\/00498254.2018.1425510","journal-title":"Xenobiotica"},{"key":"2729_CR21","unstructured":"Guidance for Industry Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendation. Draft guidance (2017) https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm292362.pdf (Accessed on 20 June, 2019)"},{"issue":"4","key":"2729_CR22","first-page":"387","volume":"24","author":"R Negroni","year":"1993","unstructured":"Negroni R, Arechavala AI (1993) Itraconazole: pharmacokinetics and indications. Arch Med Res 24(4):387\u2013393","journal-title":"Arch Med Res"},{"issue":"4","key":"2729_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/clpt.2010.119","volume":"88","author":"I Templeton","year":"2010","unstructured":"Templeton I, Peng C-C, Thummel K, Davis C, Kunze K, Isoherranen N (2010) Accurate prediction of dose-dependent CYP3A4 inhibition by Itraconazole and its metabolites from in vitro inhibition data. Clin Pharmacol Ther 88(4):499\u2013505. \nhttps:\/\/doi.org\/10.1038\/clpt.2010.119","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2729_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","volume":"77","author":"J Kirchheiner","year":"2005","unstructured":"Kirchheiner J, Brockm\u00f6ller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77(1):1\u201316. \nhttps:\/\/doi.org\/10.1016\/j.clpt.2004.08.009","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2729_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2217\/pgs.10.49","volume":"11","author":"SA Scott","year":"2010","unstructured":"Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ (2010) Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 11(6):781\u2013791. \nhttps:\/\/doi.org\/10.2217\/pgs.10.49","journal-title":"Pharmacogenomics"},{"issue":"2","key":"2729_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1128\/aac.00530-08","volume":"53","author":"VV Hynninen","year":"2009","unstructured":"Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen KJ, Korhonen T, Neuvonen PJ, Laine K (2009) Voriconazole increases while Itraconazole decreases plasma meloxicam concentrations. Antimicrob Agents Chemother 53(2):587\u2013592. \nhttps:\/\/doi.org\/10.1128\/aac.00530-08","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2729_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.taap.2003.11.015","volume":"199","author":"JH Kim","year":"2004","unstructured":"Kim JH, Sherman ME, Curriero FC, Guengerich FP, Strickland PT, Sutter TR (2004) Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smokers. Toxicol Appl Pharmacol 199(3):210\u2013219. \nhttps:\/\/doi.org\/10.1016\/j.taap.2003.11.015","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"2729_CR28","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/toxsci\/kfm012","volume":"97","author":"HM Korashy","year":"2007","unstructured":"Korashy HM, Shayeganpour A, Brocks DR, El-Kadi AO (2007) Induction of cytochrome P450 1A1 by ketoconazole and itraconazole but not fluconazole in murine and human hepatoma cell lines. Toxicol Sci:Off J Soc Toxicol 97(1):32\u201343. \nhttps:\/\/doi.org\/10.1093\/toxsci\/kfm012","journal-title":"Toxicol Sci:Off J Soc Toxicol"},{"key":"2729_CR29","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00228-018-2533-2","volume":"74","author":"A Gardin","year":"2018","unstructured":"Gardin A, Gray C, Neelakantham S, Huth F, Davidson AM, Dumitras S, Legangneux E, Shakeri-Nejad K (2018) Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9\/3A4 inducer, in healthy subjects. Eur J Clin Pharmacol 74:1593\u20131604. \nhttps:\/\/doi.org\/10.1007\/s00228-018-2533-2","journal-title":"Eur J Clin Pharmacol"},{"key":"2729_CR30","unstructured":"World Medical Association. WMA Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. \nhttps:\/\/www.wma.net\/wp-content\/uploads\/2018\/07\/DoH-Oct2008.pdf\n\n (accessed on 20 June, 2019)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02729-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02729-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T23:22:58Z","timestamp":1596669778000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02729-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02729-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted at two centers namely, SeaView Research, Inc., Miami, Florida, USA and SeaView Jacksonville, LLC Jacksonville, Florida, USA. The study protocol and subject consent forms were reviewed and approved by the Schulman Institutional Review Board, Cincinnati OH, USA. The study was conducted according to the ethical principles of the Declaration of Helsinki [] and designed in compliance with the FDA guidelines for industry on Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing and Labeling Recommendation [].","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anne Gardin, Andrea Feller, Felix Huth, Srikanth Neelakantham, Swati Dumitras, and Kasra Shakeri-Nejad are employees of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}